Stellar Biotechnologies & Life Diagnostics Announce Agreement for Stellar Brand KLH ELISA Test Kits

Stellar Biotechnologies, Inc. and Life Diagnostics, Inc. have announced that they have entered into an exclusive manufacturing and supply agreement.

Under the agreement, Life Diagnostics will utilize Stellar’s high-quality KLH to develop and manufacture Stellar brand KLH ELISA test kits for the detection of anti-KLH antibodies, for use in the growing immunotoxicity and immunology research markets.

This collaboration is expected to meet the increasing need among pharmaceutical researchers for improved test sensitivity, product consistency and analytical performance. Stellar will supply all aquaculture-derived KLH required for production of the ELISA test kits.

Life Diagnostics will manufacture the ELISA test kits, and will work closely with Stellar in the commercial marketing and sale of these products. Initially, the agreement covers six different Stellar KLH ELISA products.

Life Diagnostics’ CEO Christopher Chadwick said, "Our agreement with Stellar Biotechnologies reinforces Life Diagnostics’ commitment to providing the highest quality products and specialized reagents to global biopharmaceutical and biotechnology customers. We are pleased to be working with Stellar’s diagnostic team and look forward to producing a premium product line under the Stellar brand.”

Stellar CEO Frank Oakes commented, "As the market leader in the manufacture and commercialization of ELISA test kits for immunology research, Life Diagnostics is an excellent partner for Stellar. We share a common interest in manufacturing the highest quality products and Life’s long-standing expertise in developing leading ELISA products for the preclinical market may lead to further synergies. Stellar will also offer KLH immunizing products for use with the new KLH ELISA test kits. The Stellar KLH product line provides pharmaceutical researchers with a spectrum of consistent, standardized, quality reagents and materials. We look forward to offering these products to the research and clinical markets in early 2012.”